Insmed Inc

Insmed’s Brinsupri earns EU approval as the first‑in‑class therapy for non‑cystic fibrosis bronchiectasis, opening a new market and boosting investor interest.

Insmed Inc. is poised for a potential uptick as it prepares to present Phase 3 ASPEN trial data for its BRINSUPRI therapy, which could secure a first-to-market position in a niche patient population and unlock substantial revenue potential.

Insmed Inc.’s stock price surged to a new 52-week high after analyst upgrades and the FDA approval of its treatment for non-cystic fibrosis bronchiectasis, BRINSUPRI.

Insmed Inc has announced positive results from its Phase 2b study for Pulmonary Arterial Hypertension, marking a significant breakthrough in rare disease treatment and boosting investor confidence in the biopharmaceutical sector.

Insmed Inc, a biopharmaceutical company, has seen a significant surge in its stock price following promising trial results for its pulmonary arterial hypertension treatment, positioning it as a leader in the biotech sector.

Insmed Inc, a biopharmaceutical company, has seen a significant surge in its stock price following promising trial results for its pulmonary arterial hypertension treatment, positioning it as a leader in the biotech sector.

Insmed Inc.’s stock surges after a Phase 2b study of its Treprostinil Palmitil Inhalation Powder shows positive results in treating Pulmonary Arterial Hypertension.

Insmed Inc. reported strong Q1 2025 financial results, with $92.8 million in revenue, a 23% increase from the same period in 2024, driven by growth in its flagship product ARIKAYCE.